Registered title, quoted from ClinicalTrials.gov
Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital of Soochow University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07002099, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically confirmed primary CNS lymphoma (PCNSL) or secondary CNS lymphoma (SCNSL) with CNS-only involvement.
Inclusion criterion 2
At least one measurable brain lesion ≥1 cm in diameter, or positive cerebrospinal fluid (CSF) cytology/flow cytometry for patients with leptomeningeal disease.
Inclusion criterion 4
Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.
Inclusion criterion 5
Absolute neutrophil count (ANC) ≥ 1.0 × 10⁹/L
Inclusion criterion 7
Platelets ≥ 75 × 10⁹/L
Inclusion criterion 8
Hemoglobin ≥ 80 g/L
Inclusion criterion 9
Total bilirubin ≤ 1.5 × ULN (or ≤ 3 × ULN if liver involvement)
Inclusion criterion 10
ALT and AST ≤ 2.5 × ULN (or ≤ 5 × ULN if liver involvement)
Inclusion criterion 11
Creatinine clearance ≥ 30 mL/min (Cockcroft-Gault formula)
Inclusion criterion 12
INR ≤ 1.5 × ULN; APTT within 10 seconds of normal
Inclusion criterion 13
Known active hepatitis B (HBV), hepatitis C (HCV), or HIV infection.
Exclusion criterion 12
Negative serum pregnancy test for women of childbearing potential.
Inclusion criterion 15
Pregnant or breastfeeding women, or subjects unwilling to use medically accepted effective contraception during the study and for 6 months after the last dose.
Exclusion criterion 16
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07002099, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age ≥ 18 years, male or female.
- Histologically confirmed primary CNS lymphoma (PCNSL) or secondary CNS lymphoma (SCNSL) with CNS-only involvement.
- Ineligible for autologous stem cell transplantation based on clinical assessment or patient refusal.
- At least one measurable brain lesion ≥1 cm in diameter, or positive cerebrospinal fluid (CSF) cytology/flow cytometry for patients with leptomeningeal disease.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.
- Adequate organ function, including:
- Absolute neutrophil count (ANC) ≥ 1.0 × 10⁹/L
- Platelets ≥ 75 × 10⁹/L
- Hemoglobin ≥ 80 g/L
- Total bilirubin ≤ 1.5 × ULN (or ≤ 3 × ULN if liver involvement)
- ALT and AST ≤ 2.5 × ULN (or ≤ 5 × ULN if liver involvement)
- Creatinine clearance ≥ 30 mL/min (Cockcroft-Gault formula)
- INR ≤ 1.5 × ULN; APTT within 10 seconds of normal
- Estimated life expectancy of ≥ 3 months.
- Negative serum pregnancy test for women of childbearing potential.
- Ability to understand and willingness to sign a written informed consent form.
Exclusion Criteria:
- CNS involvement limited to intraocular lymphoma only.
- Prior systemic therapy for CNS lymphoma.
- SCNSL with active systemic (non-CNS) disease involvement.
- Uncontrolled intracranial hypertension.
- Clinically significant or unstable cardiovascular disease, including:
- Myocardial infarction within 6 months
- Unstable angina within 3 months
- Uncontrolled arrhythmias (e.g., ventricular tachycardia/fibrillation)
- Congestive heart failure NYHA class ≥ III
- LVEF < 50% by echocardiography
- Other severe uncontrolled medical conditions, including active infections requiring systemic therapy.
- Known active hepatitis B (HBV), hepatitis C (HCV), or HIV infection.
- Active gastrointestinal dysfunction that interferes with the ability to swallow or absorb oral medication.
- Prior treatment with selective inhibitor of nuclear export (SINE) compounds, including selinexor.
- Concurrent malignancy, except for adequately treated basal/squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ of the cervix, prostate, or breast.
- Pregnant or breastfeeding women, or subjects unwilling to use medically accepted effective contraception during the study and for 6 months after the last dose.
- Any condition which, in the investigator's judgment, would make the patient unsuitable for study participation.
Quoted from ClinicalTrials.gov, NCT07002099, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07002099, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.